| dc.creator | González R,Margarita | |
| dc.creator | Paquién M,Christine | |
| dc.creator | Asenjo M,Sylvia | |
| dc.creator | Gleisner E,Andrea | |
| dc.creator | Kirsten L,Lilian | |
| dc.creator | Bustamante C,Marcelo | |
| dc.date | 2001-02-01 | |
| dc.date.accessioned | 2019-11-14T12:51:49Z | |
| dc.date.available | 2019-11-14T12:51:49Z | |
| dc.identifier | https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872001000200003 | |
| dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/115019 | |
| dc.description | Background: Advanced glycation end products are associated with chronic complications of diabetes mellitus. This glycation process renders many proteins immunogenic. Aim: To detect the presence of antibodies against albumin, collagen and low density lipoprotein glycation products in boys and teenagers with diabetes mellitus. Patients and methods: Thirty one patients with diabetes mellitus type I, aged 11±3.8 years and with a mean duration of disease of 3.7±2.7 years and 31 healthy controls aged 12.4±5.3 years were studied. Antibodies against glycation end products were detected by ELISA and results were expressed as a ratio of the optical density of the glycated protein/optical density of the native protein. Results: Diabetic patients and healthy controls did not have antibodies against albumin glycation end products. Diabetics had higher levels of antibodies than controls for collagen glycation end products (2.6±0.4 and 1.8±0.2 respectively, p< 0.01) and low density lipoprotein glycation end products (3.07±0.92 and 2.2±0.72 respectively, p< 0.05). Conclusions: The biological role of these antibodies is not clear. They could be a depuration mechanism for glycation end products or contribute to chronic complications of diabetes mellitus (Rev Méd Chile 2001; 129: 141-48). | |
| dc.format | text/html | |
| dc.language | es | |
| dc.publisher | Sociedad Médica de Santiago | |
| dc.relation | 10.4067/S0034-98872001000200003 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | Revista médica de Chile v.129 n.2 2001 | |
| dc.subject | Antibodies | |
| dc.subject | Diabetes mellitus, insulin-dependent | |
| dc.subject | Glycosylation and products | |
| dc.title | Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1 | |
